Skip to main content

Day: October 14, 2020

SmartCard Marketing Systems Inc. (OTC:SMKG) Announces Completion of OriginatorX Ethereum Blockchain Issuing and Publishing Tokens Platform for Equity, Assets and Loyalty Points Offerings with Conversions to Units

New York, NY, Oct. 14, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — SmartCard Marketing Systems Inc. (OTC:SMKG) announced today that its Managed Partnership division completed the staging environment of the OriginatorX platform host for Ethereum (ERC20) Blockchain for ICOs, Crypto and Alternative derivatives offerings with the ability of Underwriting and Smart-Contracts auctions, sales and auditing management. Market OverviewThe Digital Asset Management Market (henceforth, referred to as the market studied) was valued at USD 2541.8 Million in 2019, and it is expected to reach USD 7756.1 Million by 2025, registering a CAGR of 21.23%, during the period of 2020-2025. Artificial Intelligence, including facial recognition, has been introduced to the world of DAM.  https://www.mordorintelligence.com/industry-reports/digital-asset-management-dam-market   SmartCard...

Continue reading

22nd Century Group Achieves Breakthrough Technology; Granted New Patent for Reducing Nicotine in Tobacco Plants

WILLIAMSVILLE, N.Y., Oct. 14, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant-based, life science company driven by next generation biotechnology, today announced it was granted a new U.S. patent related to the reduction of nicotine in the tobacco plant. The new technology provides 22nd Century with a rapid pathway to introduce very low nicotine traits into virtually any variety of tobacco, including bright, burley, oriental, and cigar tobacco varieties.“We are very pleased to receive this patent which reflects the ingenuity and expertise of our talented scientific team. This new technology allows us to reduce nicotine in any tobacco variety. Importantly, this breakthrough further demonstrates that the FDA’s Comprehensive Plan for Tobacco and Nicotine Regulation...

Continue reading

Tree Island Announces Five Year Union Collective Bargaining Agreement

VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) — Tree Island Steel Ltd. (“Tree Island” or the “Company”) (TSX:TSL) announced today that its operating company, Tree Island Industries Ltd. and Teamsters Local Union No. 213 have successfully concluded a new five-year collective agreement. The agreement, which covers hourly production employees at the Richmond, BC manufacturing facility, was ratified on October 14, 2020, and provides continued stability for our customers, employees, suppliers and other stakeholders.“We are very pleased to have achieved a long-term agreement in partnership with the Teamsters, and we wish to thank the bargaining unit and its members for their ongoing engagement and commitment in supporting the sustained growth of Tree Island as a premier supplier of wire and wire products,” said Remy Stachowiak,...

Continue reading

Fastest 5G Network in the World Just Launched in San Francisco

Verizon customers in CA get access to the unprecedented performance of 5G Ultra Wideband with game-changing speeds and access to 5G NationwideWhat You Need to Know:Today Verizon announced a huge leap forward in this new era of technology-led disruption that will specifically benefit customers in CAVerizon launched the unprecedented performance of its 5G Ultra Wideband service in San FranciscoVerizon continues to innovate and advance 5G technology, doubling the download speeds on the fastest 5G in the world in some locationsVerizon 5G nationwide service is available to more than 200 million people across 1,800 cities in the USSAN FRANCISCO, Oct. 14, 2020 (GLOBE NEWSWIRE) — Verizon 5G Ultra Wideband service is live in parts of San Francisco. This marks a huge leap forward in this new era of technology-led disruption and innovation....

Continue reading

Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Initial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® (nivolumab) in patients with solid tumorsAn update from the melanoma & non-melanoma skin cancer patients enrolled into the Phase 1/2 clinical trial of RP1 in combination with Opdivo® (nivolumab)WOBURN, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) — Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that data with the Company’s lead product candidate, RP1, along with initial single agent safety and efficacy data with RP2 in advanced solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting being held virtually from November 9-14, 2020.The abstracts for these...

Continue reading

Mandalay Resources Corporation tillkännager produktions- och försäljningsresultaten för tredje kvartalet 2020 och reviderad prognos för helåret 2020

TORONTO, Oct. 14, 2020 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännagav idag sina produktions- och försäljningsresultat för tredje kvartalet 2020.Produktionshöjdpunkter för tredje kvartalet 2020:22 793 säljbara gulduns producerades under tredje kvartalet 2020, bolagets bästa konsoliderade kvartalsvisa säljbara guldproduktion sedan fjärde kvartalet 2017En förbättring av den konsoliderade säljbara guldproduktionen för fjärde kvartalet i följd26 001 uns guldekvivalent såldes under tredje kvartalet 2020, den största mängden för bolaget sedan första kvartalet 2018Vi förväntar oss att uppfylla eller överträffa vår ursprungliga konsoliderade produktionsprognos för 2020 vad beträffar guldekvivalent.Under tredje kvartalet 2020 producerade Mandalay en konsoliderad mängd motsvarande...

Continue reading

HighCo: Q3 2020 Gross Profit

Aix-en-Provence, 14 October 2020 (6.00 p.m.)HIGHCO: Q3 2020 BETTER THAN EXPECTED WITH A DECLINE LIMITED TO 2.1% (GP)Q3 Business activity higher than expected (GP)Q3 20201 gross profit of €21.83 M, down 2.1% on a reported basis and LFL2.9-month 20201 gross profit of €62.24 M, a decrease of 11.7% on a reported basis and LFL2.Slight growth in Digital: Q3 up 1.1% LFL, 9-month YTD down 6% LFL.Decline in France less steep than expected: Q3 down 4.2% LFL, 9-month YTD down 11.4% LFL.Growth in International business: Q3 up 4.7% LFL, 9-month YTD down 12.5% LFL.Net cash of €6 M at end-September 2020; €30 M government-backed loan unusedAdjusted guidanceBusiness decline expected between 5% and 7% for H2 2020.2020 adjusted operating margin3 forecast at more than 12%. 1 Unaudited data.2 Like for like: Based on a comparable scope and at constant exchange...

Continue reading

HIGHCO : Marge Brute T3 2020

Aix-en-Provence, le 14 octobre 2020 (18h)HIGHCO : T3 2020 MEILLEUR QUE PREVU AVEC UN REPLI LIMITE A -2,1% (MB)Niveau d’activité au T3 supérieur aux attentes (MB)Marge brute (MB) T3 2020(1) de 21,83 M€ en repli de -2,1% à données publiées et à PCC(2).MB 9 mois 2020(1) de 62,24 M€ en baisse de -11,7% à données publiées et à PCC(2).Légère croissance du Digital : T3 PCC à +1,1% ; 9 mois PCC à -6,0%.Baisse en France moins forte qu’attendue : T3 PCC à -4,2% ; 9 mois PCC à -11,4%.Croissance à l’International : T3 PCC à +4,7% ; 9 mois PCC à -12,5%.Cash net de 6 M€ à fin septembre 2020 ; PGE de 30 M€ non utiliséGuidances préciséesRepli d’activité au S2 2020 attendu entre -5% et -7%.Marge opérationnelle ajustée(3) 2020 attendue supérieure à 12%. (1) Données non auditées.(2) PCC : à périmètre comparable et à taux de change constants (i.e. en appliquant...

Continue reading

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients

Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S.Studies are complementary and address both dose duration and disease stageRapid enrollment expected for both geographiesSAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib in mild, moderate and severe COVID-19 patients.The Brazil study is a Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19, particularly looking at the potential clinical benefits of the drug associated with its broad ability (mode of action) to reduce inflammatory cytokine storm. The...

Continue reading

Glatfelter Corporation to Report Earnings on November 3rd

CHARLOTTE, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) — Glatfelter Corporation (NYSE: GLT), announced today that it expects to issue its 2020 third-quarter results on Tuesday, November 3, 2020. Management will hold a conference call at 11:00 AM (ET) that morning to discuss the Company’s results. Glatfelter’s earnings release and an accompanying financial supplement, which includes significant financial information to be discussed on the conference call, will be available on its Investor Relations website at http://www.glatfelter.com/about_us/investor_relations/default.aspx.About GlatfelterGlatfelter is a leading global supplier of engineered materials. The Company’s high-quality, innovative and customizable solutions are found in tea and single-serve coffee filtration, personal hygiene and packaging products as well as home improvement...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.